Bruce Chang-Gu

Mr. Bruce Chang-Gu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2020 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
BCBruce Chang-Gu
Bruce Chang-Gu
DBDevin Bradburn
Devin Bradburn
PYPhilip M. Yangyuoru
Philip M. Yangyuoru
RRRick Russell
Rick Russell
DHX36 is a eukaryotic DEAH/RHA family helicase that disrupts G-quadruplex structures (G4s) with high specificity, contributing to regulatory roles of G4s. Here we used a DHX36 truncation to examine the roles of the 13-amino acid DHX36-specific motif (DSM) in DNA G4 recognition and disruption. We found that the DSM promotes G4 recognition and specificity by increasing the G4 binding rate of DHX36 without affecting the dissociation rate. Further, for most of the G4s measured, the DSM has little or no effect on the G4 disruption step by DHX36, implying that contacts with the G4 are maintained through the transition state for G4 disruption. This result suggests that partial disruption of the G4 from the 3’ end is sufficient to reach the overall transition state for G4 disruption, while the DSM remains unperturbed at the 5’ end. Interestingly, the DSM does not contribute to G4 binding kinetics or thermodynamics at low temperature, indicating a highly modular function. Together, our results animate recent DHX36 crystal structures, suggesting a model in which the DSM recruits G4s in a modular and flexible manner by contacting the 5’ face early in binding, prior to rate-limiting capture and disruption of the G4 by the helicase core.

18 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MSMark Sowers
Mark Sowers
JCJames W Conrad
James W Conrad
BCBruce Chang-Gu
Bruce Chang-Gu
ECEllie Cherryhomes
Ellie Cherryhomes
LHLinda C. C Hackfeld
Linda C. C Hackfeld
LSLawrence Sowers
Lawrence Sowers
Although genomic DNA is predominantly duplex under physiological conditions, particular sequence motifs can favor the formation of alternative secondary structures, including the G-quadruplex. These structures can exist within gene promoters, telomeric DNA, and regions of the genome frequently found altered in human cancers. DNA is also subject to hydrolytic and oxidative damage, and its local structure can influence the type of damage and its magnitude. Although the repair of endogenous DNA damage by the base excision repair (BER) pathway has been extensively studied in duplex DNA, substantially less is known about repair in non-duplex DNA structures. Therefore, we wanted to better understand the effect of DNA damage and repair on quadruplex structure. We first examined the effect of placing pyrimidine damage products uracil, 5-hydroxymethyluracil, the chemotherapy agent 5-fluorouracil, and an abasic site into the loop region of a 22-base telomeric repeat sequence known to form a G-quadruplex. Quadruplex formation was unaffected by these analogs. However, the activity of the BER enzymes were negatively impacted. Uracil DNA glycosylase (UDG) and single-strand selective monofunctional uracil DNA glycosylase (SMUG1) were inhibited, and apurinic/apyrimidinic endonuclease 1 (APE1) activity was completely blocked. Interestingly, when we performed studies placing DNA repair intermediates into the strand opposite the quadruplex, we found that they destabilized the duplex and promoted quadruplex formation. We propose that while duplex is the preferred configuration, there is kinetic conversion between duplex and quadruplex. This is supported by our studies using a quadruplex stabilizing molecule, pyridostatin, that is able to promote quadruplex formation starting from duplex DNA. Our results suggest how DNA damage and repair intermediates can alter duplex-quadruplex equilibrium.

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
BCBruce Chang-Gu
Bruce Chang-Gu
GGGeorge Golovko
George Golovko
ADAnthony P. D’aNdrea
Anthony P. D’aNdrea
KKKamil Khanipov
Kamil Khanipov
Recent studies have reported a link between elevated B12 levels and increased incidence of malignancies. In this study, we compare the association between B12 levels and adverse outcomes in colon cancer, including metastases and mortality. A globally federated multi-institutional database identified patients with colon cancer who had at least one B12 measurement within 1 year of diagnosis. Patients were stratified by B12 status (normal: 300–1,000, elevated: >1,000, and low: <300 pg/mL). Median overall survival (mOS) was compared via log-rank test and Cox proportional hazards models. The incidence of cancer metastases and elevated liver enzymes within 1 year of diagnosis was analyzed and compared using risk ratios. Further gene expression analysis of 283 colon cancer samples from The Cancer Genome Atlas (TCGA) and 304 normal colon tissues from the Genotype-Tissue Expression (GTEx) project was performed. A total of 37,106 patients were identified by TriNetX. High B12 (n = 6,523; mOS = 59.4 months) was associated with a decreased mOS compared with normal (n = 23,965; mOS = 129.8 months) and low (n = 5,167; mOS = 137.3 months) B12 patients. Patients with elevated B12 had higher metastatic involvement and tumor stage at diagnosis and a higher 1-year incidence of all metastases, liver, lung, and peritoneal metastases [risk ratio with 95% confidence intervals of 1.30 (1.24–1.36), 1.56 (1.45–1.68), 1.43 (1.27–1.61), 1.39 (1.24–1.55), respectively]. Gene expression analysis of TCGA and GTEx identified the expression of the B12-dependent methionine synthase (MTR) to be elevated in colon cancer tissue, and increased MTR expression was associated with decreased colon cancer survival (65.8 months vs. undefined). These findings identify the potential clinical relevance of B12 as a biomarker for colon cancer metastases and survival. Significance: Elevated B12 has been reported to be associated with increased cancer incidence; however, its role as a prognostic marker in colon cancer is unclear. In this multi-institutional study investigating clinical outcomes of patients with colon cancer, we demonstrate elevated B12 as a potential biomarker for colon cancer metastases and survival.

1 August 2025 in Molecules
Verified
Journal Article
Open access
PDF file
JHJason Herring
Jason Herring
MSMark Sowers
Mark Sowers
JCJames Conrad
James Conrad
LHLinda C. C Hackfeld
Linda C. C Hackfeld
BCBruce Chang-Gu
Bruce Chang-Gu
LSLawrence Sowers
Lawrence Sowers
The incorporation of nucleoside analogs into DNA by polymerases, followed by their removal through base excision repair (BER), represents a promising strategy for cancer chemotherapy. In this study, we investigated the incorporation and cytotoxic effects of several nucleoside analogs—some of which are epigenetic reprogramming intermediates—in the U87 glioblastoma cell line. We found that two analogs, 5-hydroxymethyl-2′-deoxyuridine (5HmdU) and trifluorothymidine (TFT), are both cytotoxic and are efficiently incorporated into genomic DNA. In contrast, the 5-carboxy analogs—5-carboxy-2′-deoxyuridine (5CadU) and 5-carboxycytidine (5CadC)—showed no cytotoxicity and were not incorporated into DNA. Interestingly, 5-hydroxymethyl-2′-deoxycytidine (5HmdC) was cytotoxic but was not directly incorporated into DNA. Instead, it was deaminated into 5HmdU, which was then incorporated and likely responsible for the observed toxicity. 5HmdU is actively removed from DNA through the BER pathways. In contrast, TFT remains stably incorporated and is neither excised by BER nor does it hydrolyze into 5CadU—a known substrate for the DNA glycosylase SMUG1. We also found that N6-benzyladenosine (BzAdo), an inhibitor of the enzyme 2′-deoxynucleoside 5′-phosphate N-hydrolase (DNPH1), enhances the cytotoxicity of 5HmdU. However, the thymidine phosphorylase inhibitor tipiracil hydrochloride (TPI) does not increase the cytotoxic effect of TFT in U87 cells. Together, these findings highlight 5HmdU and TFT as promising chemotherapeutic agents for glioblastoma, each with distinct mechanisms of action and cellular processing.

18 June 2026
Verified
Other
Open access
BCBruce Chang-Gu
Bruce Chang-Gu
GGGeorge Golovko
George Golovko
ADAnthony P. D’ANdrea
Anthony P. D’ANdrea
KKKamil Khanipov
Kamil Khanipov
B12 status and colon cancer survival. A, Kaplan–Meier analysis of B12 status in unmatched patients with colon cancer and mortality. Patients with colon cancer and elevated B12 measurements had a decreased mOS (mOS = 59.4 months) compared with patients with normal (mOS = 129.8 months) and low B12 (mOS = 137.3 months). B, Forest plot summarizing pairwise comparisons with HR and 95% CI. Statistical significance was determined by the log-rank test.

18 June 2026
Verified
Other
Open access
BCBruce Chang-Gu
Bruce Chang-Gu
GGGeorge Golovko
George Golovko
ADAnthony P. D’ANdrea
Anthony P. D’ANdrea
KKKamil Khanipov
Kamil Khanipov
Kaplan-Meier curves based on B12 status after propensity score matching.